Checkpoint Therapeutics Inc (CKPT) - Total Liabilities
Based on the latest financial reports, Checkpoint Therapeutics Inc (CKPT) has total liabilities worth $17.87 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See CKPT net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Checkpoint Therapeutics Inc - Total Liabilities Trend (2014–2024)
This chart illustrates how Checkpoint Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Checkpoint Therapeutics Inc's balance sheet.
Checkpoint Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Checkpoint Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hunan Hengguang Technology Co.Ltd.
SHE:301118
|
China | CN¥1.17 Billion |
|
WEIHAI CITY COMM.BK H 1
F:8K0
|
Germany | €469.14 Billion |
|
Van de Velde NV
BR:VAN
|
Belgium | €42.28 Million |
|
Monro Muffler Brake Inc
NASDAQ:MNRO
|
USA | $965.03 Million |
|
Ulusoy Elektrik Imalat
IS:ULUSE
|
Turkey | TL7.13 Billion |
|
Alantra Partners S.A.
MC:ALNT
|
Spain | €100.78 Million |
|
Brunel International NV
AS:BRNL
|
Netherlands | €293.65 Million |
|
Quad Graphics Inc
NYSE:QUAD
|
USA | $1.07 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Checkpoint Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See CKPT equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Checkpoint Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Checkpoint Therapeutics Inc (2014–2024)
The table below shows the annual total liabilities of Checkpoint Therapeutics Inc from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $20.10 Million | +9.07% |
| 2023-12-31 | $18.43 Million | -43.78% |
| 2022-12-31 | $32.77 Million | +26.14% |
| 2021-12-31 | $25.98 Million | +260.01% |
| 2020-12-31 | $7.22 Million | -11.11% |
| 2019-12-31 | $8.12 Million | -37.99% |
| 2018-12-31 | $13.09 Million | +105.48% |
| 2017-12-31 | $6.37 Million | +73.48% |
| 2016-12-31 | $3.67 Million | -13.74% |
| 2015-12-31 | $4.26 Million | -- |
| 2014-12-31 | $0.00 | -- |
About Checkpoint Therapeutics Inc
Checkpoint Therapeutics, Inc., a commercial -stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is UNLOXCYT, which is in Phase 1 clinical trial to treat patients with selected recurrent or m… Read more